Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Justin Kurian
Institution:
Prelude Therapeutics Incorporated (United States)
Observed institution:
Prelude Therapeutics Incorporated (United States)
ORCID:
0009-0006-5412-3681
Observed ORCID:
0009-0006-5412-3681
OpenAlex ID:
A5121773671
Abstract 5793: First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile
2026
·
Monisha Sivakumar
, Sarah Pawley
, et al.
·
Cancer Research
·
2
Figure S10 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S2 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S1 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S11 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S5 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S5 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S7 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S3 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S1 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S8 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Data from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S2 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S9 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S3 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S7 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Show more works
View as search
Works count:
20
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type